DALLAS, April 6, 2015 /PRNewswire/ --
RnRMarketResearch.com adds "Bronchopulmonary Dysplasia - Pipeline Review, H1 2015" therapeutic market research report with latest updates, data and information to its online business intelligence library.
The report "Bronchopulmonary Dysplasia-Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Bronchopulmonary Dysplasia. Bronchopulmonary dysplasia or BPD is a serious lung condition that affects infants. Bronchopulmonary dysplasia mostly affects premature infants who need oxygen therapy. Many infants born with bronchopulmonary dysplasia exhibit signs and symptoms of respiratory distress syndrome, including the following: Tachypnea, Tachycardia, Increased respiratory effort & frequent desaturations.
This report is complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchopulmonary Dysplasia and special features on late-stage and discontinued projects.
Companies discussed in this report include Airway Therapeutics, Inc., Chiesi Farmaceutici SpA
Ikaria Inc., MediPost Co., Ltd., Syntrix Biosystems, Inc.
Drug Profiles discussed in this report include AT-100, CG-100, nitric oxide, Pneumostem, R-190, R-908, small Molecules for Bronchopulmonary Dysplasia, SX-682. Order a Purchase copy of this reportathttp://www.rnrmarketresearch.com/contacts/purchase?rname=314374. (This is a premium report priced at US$2000 for a single user License.)
Featured News & Press Releases cover by this report include: Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung; Aug 12, 2014: MediPost, lung disease stem cell treatment drug 'Pneumostem' application for US clinical trial; Feb 06, 2014: Stem cells to treat lung disease in preterm infants; Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem; May 31, 2012: Medipost Submits Application To KFDA For Pneumostem Clinical Trial; Feb 27, 2012: Ikaria Completes Patient Enrollment In Pivotal Phase III Trial For Bronchopulmonary Dysplasia; Jan 05, 2011: Ikaria Receives Marketing Exclusivity Extension For Inomax From FDA.
Scope of this report includes: a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia; The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; report reviews key players involved in the therapeutics development for Bronchopulmonary Dysplasia and enlists all their major and minor projects; report summarizes all the dormant and discontinued pipeline projects; A review of the Bronchopulmonary Dysplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Bronchopulmonary Dysplasia pipeline on the basis of target, MoA, route of administration and molecule type as well as Latest news and deals relating related to pipeline products.
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bronchopulmonary Dysplasia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .
About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact:
Ritesh Tiwari
TX,Dallas North- Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@rnrmarketresearch.com
